Meeting
2019 Gastrointestinal Cancers Symposium
The association of 5FU-based chemotherapy with pathological response or survival compared to carbo/taxol with locally advanced resectable esophageal cancer.
Authors
Mohammed Al-Jumayli
Kansas University Cancer Center, Kansas, KS
Mohammed Al-Jumayli , Saqib Abbasi , Anup Kasi , Anwaar Saeed
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 165)
DOI
10.1200/JCO.2019.37.4_suppl.165
Abstract #
165
Poster Bd #
M17
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Influence of tumor response and treatment schedule on the distribution of tumor recurrence in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
First Author: Kristien M. Jipping
Poster
2012 Gastrointestinal Cancers Symposium
Retrospective analysis of neoadjuvant chemoradiotherapy for esophageal cancer: The Knight Cancer Institute experience.
First Author: Faisal A Siddiqui
Poster
2023 ASCO Breakthrough
Impact of pathological response and recurrence pattern on the survival of patients who develop recurrence from neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (ESCC).
First Author: Chien Huai Chuang
Poster
2022 ASCO Annual Meeting
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results.
First Author: Darren Cowzer